✓ No loaded language, vague sourcing, or framing detected.
The FDA has granted approval for Lipfendra, a cholesterol-lowering pill developed by Merck. The medication targets patients suffering from hypercholesterolemia, particularly those with hereditary variations of the disease.
Our neutral summary
The FDA has granted approval for Lipfendra, a cholesterol-lowering pill developed by Merck. The medication targets patients suffering from hypercholesterolemia, particularly those with hereditary variations of the disease.
The reporting belongs to New York Post; we don't reproduce it.
No note attached
on this article.
FDA signs off on Merck’s cholesterol-lowering pill — the first oral treatment of its kind
FDA Approves Merck's Cholesterol-Lowering Pill Lipfendra